Absci (ABSI) Corporate presentation summary

AI-driven drug discovery platform

• Integrated AI-native platform combines advanced computational models with a 77,000 ft² automated wet lab for rapid, de novo antibody design and optimization.

• Platform enables industrialized, capital-efficient drug discovery, reducing timelines from years to months and costs from $50-100M to $10-15M per program.

• Proprietary models can design antibodies against challenging targets with minimal prior data, supporting multi-epitope and functional optimization.

• Lab-in-the-loop validation ensures AI-designed antibodies meet criteria for specificity, developability, and manufacturability.

• Demonstrated success in cross-species optimization, multi-variant specificity, and pH-sensitive binding.

Clinical pipeline and lead programs

• ABS-201, an anti-prolactin receptor antibody, is advancing for androgenetic alopecia (AGA) and endometriosis, with Phase 1/2a trials initiated in December 2025.

• AGA program targets a large, underserved population (~80M in the US), aiming for durable hair regrowth with infrequent dosing and superior efficacy to current therapies.

• Endometriosis program leverages a novel, non-hormonal mechanism to address pain and lesion growth, targeting a US market of 9M patients.

• ABS-101 for IBD shows improved half-life and tissue penetration, ready for partnering.

• Multiple early-stage programs in immunology, inflammation, and metabolism are in development or available for partnership.

ABS-201: scientific rationale and preclinical data

• ABS-201 targets PRLR, shifting hair follicles to the growth phase, promoting regrowth and pigmentation restoration.

• Preclinical models show superior efficacy to minoxidil and durable hair regrowth in primates, with extended half-life and high bioavailability.

• Human genetics and ex vivo studies support safety and mechanism of action, with no major adverse effects observed in PRLR loss-of-function individuals.

• Market research indicates strong patient and clinician demand, with a potential US TAM >$25B and global TAM >$40B.

• Phase 1/2a trial designed for robust safety, PK/PD, and efficacy endpoints, with interim readouts expected in 2026.